Novartis top|line results for CANOPY|1 Phase III study support ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III ...

Novartis' Autoimmune Drug Not Up for the Challenge in Phase III ...

CANOPY-1 is studying canakinumab with immunotherapy and chemotherapy, and is expected to provide final data before the end of the year. CANOPY-A ...

Novartis Scemblix® shows superior major molecular response ...

standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia ... Results from a Phase 1 Study. Poster ...

Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON ...

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 part 2 trial. ESMO open. 2023; 8 ...

Novartis results for CANOPY-1 study support further evaluation of ...

The comprehensive CANOPY clinical trial program continues with CANOPY-A, a Phase III study investigating canakinumab as an adjuvant therapy ( ...

Amivantamab plus chemotherapy with and without lazertinib in ...

The aforementioned results supported further evaluation. MARIPOSA-2 is a global, randomized, phase III trial assessing the efficacy and safety ...

A multicenter, randomized, double-blind, phase 3 trial - PubMed

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based ...

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung ...

We conducted a global, randomized, phase 3 trial comparing lorlatinib with crizotinib in 296 patients with advanced ALK-positive NSCLC who had received no ...

Novartis investigational atrasentan Phase III study demonstrates ...

Basel, October 30, 2023 — Novartis today announced positive topline results from the interim analysis of the ongoing pivotal Phase III ALIGN ...

the Phase III SPR1NT trial | Nature Medicine

All survived without permanent ventilation at 14 months; ten (67%) maintained body weight (≥3rd WHO percentile) without feeding support through ...

Novartis Reveals New Collaborators to Beacon of Hope Initiative

Results of the trial found that SC VK2735 demonstrated up to 14.7% weight loss from baseline, with 88% of patients achieving ≥10% weight loss ...

Tepotinib Treatment in Patients With MET Exon 14–Skipping Non ...

In second-line patients with 1 prior therapy (n = 92), ORR was 45.7% (95% CI, 35.2%-56.4%) and mDOR was 12.6 (95% CI, 8.3-18.5) months (eTable 4 ...

Fast progression in non–small cell lung cancer

... results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel ... 1 10 Data on HPD from randomized phase III studies ...

ESMO Congress 2021 | OncologyPRO

LBA17_PR - Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor ...

Novartis bid to repurpose rare disease drug for cancer falls short in ...

Novartis is still running one more trial of canakinumab in lung cancer, a Phase 2 study called CANOPY-N that's testing treatment before surgery ...

Five-year follow-up of ZUMA-1 supports the curative potential of ...

Investigator-assessed response, survival, safety, and pharmacokinetics were assessed in patients who had received treatment. The objective ...

Novartis investigational iptacopan Phase III study demonstrates ...

Basel, December 11, 2023 — Novartis today announced positive topline results from the six-month, double-blind period of the Phase III APPEAR-C3G ...

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast ...

We selected the ribociclib dose of 600 mg per day on the basis of the results of a phase 1 study involving patients with advanced cancer.

ClinicalTrials.gov: Home

... phase 1 trials to investigate how or whether a drug affects the body. They ... As of January 1, 2020, initial results submissions for applicable clinical trials ...

Novartis to go on studying Ilaris in NSCLC despite CANOPY-1 trial ...

Despite the failure of the Phase III pivotal CANOPY-1 trial, Novartis ... top-line results show that clinically meaningful improvements in ...